Strontium-89
| General | |
|---|---|
Decay mode | Decay energy (MeV) |
| Beta decay | 1.492[1] |
| Isotopes of strontium Complete table of nuclides | |
Strontium-89 (89
Sr
) is a
yttrium-89. Strontium-89 has an application in medicine.[2]
History
Strontium-89 was first synthesized in 1937 by D. W. Stewart et al. at the
yttrium-86 using cyclotrons, and described the therapeutic use of strontium.[6]
Physiological effects and medical use
GE Healthcare and used for purposes such as prostate cancer treatment.[7]
Strontium belongs to the same periodic family as
In circumstances where cancer patients have widespread and painful bony metastases, the administration of 89Sr results in the delivery of
opioid analgesics
, an increase in time until further radiation is needed, and a decrease in tumour markers.
See also
- Isotopes of strontium
- Alpharadin, radium-223 with similar clinical use
References
- PMID 11916063.
- doi:10.1016/j.nuclphysa.2003.11.001. Archived from the original(PDF) on 2011-07-20.
- .
- S2CID 88173163.
- OCLC 7837554.
- ^ US 2302470, Pecher, Charles, "Material and method for radiography", published 1941-05-14
- ^ "Strontium 89 (Metastron) treatment". QEH Birmingham. NHS. Retrieved 23 November 2015.
- ISBN 978-0-7817-6369-1. Retrieved 19 July 2011.
- PMID 16299924.
- PMID 9838899.